Skip to Content
Merck

SML1796

Atazanavir

≥98% (HPLC), HIV protease inhibitor, powder

Synonym(s):

1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate, BMS-232632

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C38H52N6O7
CAS Number:
Molecular Weight:
704.86
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Atazanavir, ≥98% (HPLC)

InChI

1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1

SMILES string

O=C(N[C@@H](C(C)(C)C)C(N[C@H]([C@H](CN(CC1=CC=C(C2=NC=CC=C2)C=C1)NC([C@@H](NC(OC)=O)C(C)(C)C)=O)O)CC3=CC=CC=C3)=O)OC

InChI key

AXRYRYVKAWYZBR-GASGPIRDSA-N

assay

≥98% (HPLC)

form

powder

optical activity

[α]/D -41 to -49°, c = 0.1 in ethanol

color

white to beige

solubility

DMSO: 10 mg/mL, clear

storage temp.

−20°C

Quality Level

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Atazanavir is an antiviral HIV protease inhibitor.

General description

Atazanavir inhibits the cleavage of gag and gag-pol polyproteins in human immunodeficiency virus. It is absorbed and metabolized by cytochrome P450 present in the liver. It has minimal side effects and has no effect on insulin sensitivity and serum lipid profile.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Eye Irrit. 2

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Atazanavir
Croom KF, et al.
Drugs, 69(8), 1107-1140 (2009)
Daniel W Cole et al.
Experimental cell research, 382(1), 111386-111386 (2019-05-11)
Many FDA-approved anti-cancer therapies, targeted toward a wide array of molecular targets and signaling networks, have been demonstrated to activate the unfolded protein response (UPR). Despite a critical role for UPR signaling in the apoptotic execution of cancer cells by
Saif Ahmad Khan et al.
Pharmaceutics, 12(11) (2020-11-12)
Atazanavir (ATZ) presents poor brain availability when administered orally, which poses a major hurdle in its use as an effective therapy for the management of NeuroAIDS. The utilization of nanostructured lipid carriers (NLCs) in conjunction with the premeditated use of
Masayuki Amano et al.
Scientific reports, 7(1), 12235-12235 (2017-09-28)
We report that GRL-09510, a novel HIV-1 protease inhibitor (PI) containing a newly-generated P2-crown-tetrahydrofuranylurethane (Crwn-THF), a P2'-methoxybenzene, and a sulfonamide isostere, is highly active against laboratory and primary clinical HIV-1 isolates (EC
Lisa Rosenblatt et al.
BMC infectious diseases, 16, 492-492 (2016-09-20)
A previous cohort study indicated that atazanavir (ATV), a protease inhibitor used for HIV treatment, is not associated with an increased risk of cardiovascular (CV) events. The objective of this study was to compare the risk of CV events among

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service